

The West Africa ICEMR Partnerships for Guiding Policy to Improve the Malaria Prevention and Control

Seydou Doumbia,^{1,2*} Mahamadou Toure,^{1,2} Nafomon Sogoba,¹ Michael Alifrangis,³ Mahamadou Diakite,^{1,2} Ayouba Diarra,^{1,2} Moussa Keita,¹ Drissa Konaté,¹ Sory I. Diawara,¹ Sidibé M'Baye Thiam,¹ Soumba Keita,¹ Moctar Tounkara,⁴ Idrissa Cissé,⁵ Vincent Sanogo,⁵ Mahamadou H. Magassa,⁵ Alyssa E. Barry,⁶ Peter J. Winch,⁷ Hannah C. Marker,⁷ Jeffrey G. Shaffer,⁸ Sékou F. Traoré,¹ Günter C. Müller,^{1,2} Liwang Cui,⁹ John C. Beier,¹⁰ and Jules Mihigo¹¹

¹Malaria Research and Training Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali; ²University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali; ³Centre for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark; ⁴Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; ⁵Department of Public Health, Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali; ⁶National Malaria Control Program, Ministry of Health, Bamako, Mali; ⁷School of Medicine, Deakin University, Geelong, Australia; ⁸Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; ⁹School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana; ¹⁰Division of Infectious Diseases and Internal Medicine, Department of Internal Medicine, University of South Florida, Tampa, Florida; ¹¹Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida; ¹¹U.S. President's Malaria Initiative, United States Agency for International Development Office, Bamako, Mali

Abstract. The Mali National Malaria Control Program (NMCP) recently established a phased set of goals for eliminating malaria in Mali by 2030. Over the past decade, the scale-up of NMCP-led malaria control interventions has led to considerable progress, as evidenced by multiple malariometric indicators. The West Africa International Center of Excellence in Malaria Research (WA-ICEMR) is a multidisciplinary research program that works closely with the NMCP and its partners to address critical research needs for malaria control. This coordinated effort includes assessing the effectiveness of control interventions based on key malaria research topics, including immune status, parasite genetic diversity, insecticide and drug resistance, diagnostic accuracy, malaria vector populations and biting behaviors, and vectorial capacity. Several signature accomplishments of the WA-ICEMR include identifying changing malaria age demographic profiles, testing innovative approaches to improve control strategies, and providing regular reporting on drug and insecticide resistance status. The NMCP and WA-ICEMR partnership between the WA-ICEMR and the NMCP offers a comprehensive research platform that informs the design and implementation of malaria prevention and control research programs. These efforts build local expertise and capacity for the next generation of malaria researchers and guide local policy, which is crucial in sustaining efforts toward eliminating malaria in West Africa.

BACKGROUND

Mali is a large, semiarid country in west Africa with approximately 20.3 million people.^{1,2} Over 90% of the population resides in the malaria-endemic areas in the central and southern regions of the country. The Mali National Malaria Control Program (NMCP) has set a goal to eliminate malaria by 2030.³ To achieve this goal, the NMCP has planned scaled-up coverage of evidence-based antimalarial interventions targeting 80% to 90% of Mali's risk population.³ These interventions include artemisinin-based combination therapies (ACTs), long-lasting insecticide-treated nets (LLINs), intermittent preventive treatment in pregnancy (IPTp), indoor residual spraying (IRS), and seasonal malaria chemoprevention (SMC). These efforts have yielded substantial declines in malaria morbidity and mortality, with notable improvements evidenced through multiple malariometric indicators.^{4–7} This progress has been hampered by numerous challenges and policy gaps, many of which were unanticipated. Important gaps in current malaria control policies include insufficient knowledge on the contextual effectiveness of evidence-based preventive treatment strategies (such as SMC and vector control measures such as LLINs and IRS) and limited scientific evidence to support decisions on interventions

best suited to the local context for effective malaria control.⁸ For instance, the efficacy of LLINs may vary with the biting behavior of malaria vectors, and the effectiveness of SMC may be affected by the length of malaria transmission seasons. Other gaps include inadequate monitoring of the effectiveness of current malaria control interventions. Significant challenges observed here were shifts in peak malaria transmission seasons, changes in malaria age demographic profile (particularly among children), suboptimal implementation of control interventions, resistance of *Anopheles* mosquito vectors to widely used insecticides,^{9,10} and the potential emergence of antimalarial drug resistance.^{8,11,12}

The NMCP and its partners have long prioritized operational and implementation research that applies evidence-based approaches to improve the effectiveness of control interventions. These efforts leveraged research programs through the West Africa International Center of Excellence in Malaria Research (WA-ICEMR) and the University of Sciences, Techniques and Technologies of Bamako (USTTB) to enhance the partnership between researchers and decision-makers to deal effectively with the challenges and policy gaps to malaria control. Launched in 2010, the WA-ICEMR encompasses three research focuses: epidemiology, immunogenomics, and vector ecology.^{13–15} These focuses are applied using operational, implementation, and translational research approaches and substantial research capacity-building components. The field sites for the WA-ICEMR studies include three ecological settings with variable malaria endemicity levels, seasonality, lengths of transmission, and transmission intensity.^{16,17} Because of the direct and long-

*Address correspondence to Seydou Doumbia, University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, BP 1805, Point G, Bamako, Mali. E-mail: sdoumbi@icermali.org

standing relationship between the WA-ICEMR and the NMCP, this work aims to chronicle recent advancements in malaria prevention and control policy in Mali achieved through these collaborations and provide the research community with perspectives for utilizing these approaches in malaria-endemic settings.

Stakeholder partnerships for addressing the research needs for malaria prevention and control policy. The WA-ICEMR was designed in response to research questions pertaining to Mali's high malaria burden despite the extensive deployment of established interventions. The WA-ICEMR works closely with NMCP and its partners, including the U.S. President's Malaria Initiative (PMI), the Global Fund, and the United Nations Children's Fund (UNICEF). These coordinated efforts occur through complementary and supportive roles. During the establishment of the WA-ICEMR, study investigators performed a comprehensive needs assessment through in-depth interviews, focus groups, and training workshops. Interviews were conducted with key stakeholders, including country, regional, and district health officers, using iterative approaches to define research priorities. These priorities and other collaborative initiatives are detailed in Table 1.

The research portfolio for the WA-ICEMR was defined according to feedback from its scientific advisory group and the NMCP and its PMI partners during planning meetings for developing the annual malaria operational plan.¹⁸ This collaboration facilitated the regular dissemination of research findings through organized scientific conferences and workshops.

WA-ICEMR research studies and activities supporting NMCP initiatives. NMCP approaches for reducing malaria morbidity and mortality apply targeted malaria prevention and control interventions according to the epidemiological and entomological profiles of particular geographic zones. Thus, the NMCP relies on frequent, regular, and accurate epidemiological, entomological, and climate data to ascertain the quality and impact of malaria control interventions. The WA-ICEMR is established in different ecological settings and provides a unique opportunity for accurate and real-time data assessment of the temporal and spatial changes in malaria transmission, infection, and disease. It was of interest to quantify these changes before and after launching large-scale interventions such as LLIN distribution and SMC to inform the NMCP regarding its impact and cost-effectiveness. One such initiative that the WA-ICEMR extensively studied was SMC. SMC has been supported by PMI in Mali since 2014¹⁸ and is guided through operational and implementation research by the NMCP and WA-ICEMR. A host of approaches for improving SMC effectiveness have been evaluated and performed through WA-ICEMR studies.^{6,19} For example, the WA-ICEMR and the NMCP jointly studied whether the extension of SMC was suitable for children at least 5 years of age (who are not covered by Mali's current SMC policy) and whether increasing the number of rounds in areas with longer seasonal malaria conditions would yield improved results.^{6,19,20} Another SMC implementation study involved a large community trial to assess the effectiveness of SMC for children between 5 and 9 years old using dihydroartemisinin-piperazine (DHA-PQ) as an alternative treatment strategy to the standard SMC regimen (sulfadoxine-pyrimethamine with amodiaquine [SP-AQ], clinical trial number NCT04149106). Substantial declines in malaria incidence rates were reported for populations

covered by DHA-PQ or SP-AQ, and the effectiveness of DHA-PQ in preventing malaria and improving compliance rates among children between 5 and 9 years old became apparent. After these promising results, PMI and NMCP continued to support the implementation of these extended SMC strategies. The WA-ICEMR also addressed several other research questions related to SMC and ACT treatments to guide malaria control policy. These questions focused on malaria pathogenesis, molecular diagnostic testing performance, treatment compliance, parasite genetic diversity, drug resistance markers, tests for detecting counterfeit and substandard artemisinin drugs, and the impacts of interventions on immune responses and potential rebound effects for discontinued SMC use. Through genotyping studies of *Plasmodium falciparum* parasites and whole-genome sequencing elucidating drug resistance markers, the WA-ICEMR quantified temporal changes in parasite diversity in relation to drug pressure in SMC implementation.

Vector control research is yet another topic of collaboration between the WA-ICEMR and NMCP. Vector research focuses on highly complex and heterogeneous patterns of insecticide resistance observed in Mali.^{10,21,22} These efforts underscore the importance of continuously monitoring susceptibility profiles and vector population bionomics. The WA-ICEMR addressed several research questions affecting malaria transmission, including the impacts of dry season vector ecology and insecticide resistance.^{17,22} The WA-ICEMR study sites supported the NMCP by collecting, capturing, and disseminating data on insecticide resistance and trends of malaria vector transmission in response to control interventions. The WA-ICEMR also collaborated with the WHO, resulting in a pilot multisectoral intervention to control malaria vectors that contributed to insecticide resistance mitigation.

Vector ecology studies assist in understanding malaria transmission dynamics, including identifying sources and survival strategies of vector populations during extended dry seasons. Findings from vector ecology studies performed during the dry season provide implementation research opportunities for testing the added value of malaria control strategies targeting dry season transmission, including larval control²³ and reactive treatment strategies.²⁴ Ideally, these interventions should be jointly performed with existing control tools such as LLINs and SMC. Research findings on insecticide resistance are particularly important in supporting the deployment of the next generation of LLINs.¹⁰ However, further research in this area is needed to optimize the use of these approaches, as they may have only a modest impact in the presence of mechanisms of pyrethroid resistance (other than metabolic detoxification by oxidase enzymes). Thus, where and when the next-generation LLINs might have a positive impact on malaria transmission remains an important issue, given its relatively high cost and the need for two or more compounds of different insecticide classes to make a single product to combating resistance.²⁵ The high levels of outdoor transmission observed in the studies covered here call for additional vector control tools to complement current indoor strategies. Translational research on attractive targeted sugar baits implemented at Mali field sites^{26,27} through the collaboration between the WA-ICEMR and Innovative Vector Control Consortium (IVCC) also offers new perspectives for improving vector control strategies. The WA-ICEMR has recently planned studies with the NMCP and

TABLE 1
Selected NMCP operational and implementation research priorities addressed in collaboration with the WA-ICEMR

Malaria Control Program component*	Operational challenges encountered in implementing malaria control program component	Operational research performed to mitigate operational challenges
Malaria case management and treatment	<ul style="list-style-type: none"> • Lack of adequate and current management and treatment practices at local health facilities 	<ul style="list-style-type: none"> • Performance improvement techniques offered to health workers on a regular basis to improve adherence to current clinical treatment guidelines as well as training in malaria diagnosis
Malaria in pregnancy	<ul style="list-style-type: none"> • Low health worker compliance with guidelines for administration of IPTp in health facilities • Low coverage and uptake of IPTp with three doses of SP 	<ul style="list-style-type: none"> • New service delivery strategies and behavior change interventions to increase SP compliance
SMC	<ul style="list-style-type: none"> • Limited knowledge on level of compliance, side effects and possible barriers to SMC treatment • Lack of knowledge on the long-term impact of SMC on malaria epidemiology and transmission (rebound effect on immune response, burden of the disease, parasite genotypes and possible drug resistance development) 	<ul style="list-style-type: none"> • Post-SMC surveys on compliance and possible SMC-caused side effects and drug metabolite measurement (ELISA) for compliance • SMC impact studies on prevalence and incidence of <i>Plasmodium falciparum</i> infection and disease • Cohort-based immunogenomics studies to measure the possible impact of SMC on immunological indices • Molecular/genomic surveillance of antimalarial drug resistance markers studies and potential impact on malaria incidence • Test of DHA-PQ as an alternative drug for SMC
Antimalarial drug resistance	<ul style="list-style-type: none"> • Need for evaluation of alternative drugs for SMC • Lack of knowledge on current prevalence and the possible impact of molecular antimalarial drug resistance markers relevant for treatment (ACTs) and preventive treatment 	<ul style="list-style-type: none"> • Repeated molecular surveillance of antimalarial drug resistance markers and ex vivo testing
Malaria mosquito transmission	<ul style="list-style-type: none"> • Need for updated knowledge on the impact of current vector control strategies on vector abundance, species composition, and biting behavior • Lack of knowledge on vector habitat and survival strategies through the dry season 	<ul style="list-style-type: none"> • Longitudinal monitoring of entomological parameters at WA-ICEMR study sites • Studies of vector ecology and larval source identification applying drones, ground-truthing and GIS/RS
LLIN use	<ul style="list-style-type: none"> • Lack of updated knowledge on coverage, usage, and residual effects of ITNs on adult mosquitoes • Need for evidence on the effectiveness of the deployment of next-generation ITNs 	<ul style="list-style-type: none"> • Coverage and usage patterns of ITNs regarding trends in malaria transmission • Assessment of the residual effect of insecticides • Testing for the effectiveness of next-generation ITNs
Insecticide resistance	<ul style="list-style-type: none"> • Need for regular, routine information on insecticide resistance profiles of primary malaria vectors 	<ul style="list-style-type: none"> • Continuous monitoring of susceptibility patterns in vector populations, particularly in intervention areas (molecular resistance markers, genomic surveillance)
Monitoring and evaluation	<ul style="list-style-type: none"> • Large amounts of data at both the individual and molecular levels, with limited capacity for data modeling and analysis 	<ul style="list-style-type: none"> • Assistance with analyses for routine data monitoring • Application of monitoring data to improve program implementation • Data sharing and continuous analyses of research data to assist NMCP

ACT = artemisinin-based combination therapy; DHA-PQ = dihydroartemisinin-piperazine; ELISA = enzyme-linked immunosorbent assay; GIS = geographic information systems; ITN = insecticide-treated net; IPTp = intermittent preventive treatment of malaria during pregnancy; LLIN = long-lasting insecticide-treated bed net; NMCP = Mali National Malaria Control Program; RS = remote sensing; SMC = seasonal malaria chemoprevention; SP = sulfadoxine-pyrimethamine; WA-ICEMR = West Africa International Center of Excellence in Malaria Research.

* Performed by the Mali NMPC.

PMI in more extensive randomized trials to determine the effectiveness of these new approaches.

Research capacity building supporting malaria control and prevention. The WA-ICEMR was established to strengthen local research leadership to build sustainable research capacity to guide malaria control strategies. Local Mali researchers lead the WA-ICEMR multidisciplinary research projects in collaboration with international malaria experts. The research studies generated through the WA-ICEMR has also contributed to research career development for numerous junior investigators. For instance, sponsored research provided internship and thesis opportunities for

graduate students (at both the master's and doctoral levels) to address malaria prevention and control research questions. Numerous manuscripts led by Malian junior investigators from these efforts have since been published (Table 2).

The WA-ICEMR also leveraged a host of NIH research training grants, focusing on operational research and bioinformatics and data science approaches to training the next generation of malaria researchers in West Africa. One example is the West Africa Center of Excellence in Bioinformatics Training, which provides enhanced short- and long-term bioinformatics and data science research training and funding for independent pilot projects for students and postdoctoral

TABLE 2
Selected manuscripts led by Malian junior investigators since 2020

Lead author	Year published	Topic
Konate ⁶	2021	Seasonal malaria chemoprevention efficacy and community acceptance
Touré ²⁸	2022	Impact of interventions on malaria trends
Konaté ¹⁹	2020	Seasonal malaria chemoprevention efficacy
Ateba ²⁹	2020	Space-time trends in malaria incidence
Konaté ³⁰	2021	Seasonal malaria chemoprevention and nutrition
Ateba ³¹	2020	Malaria incidence prediction
Keita ²²	2020	Indoor residual spraying and malaria incidence
Keita ³²	2021	Malaria insecticide resistance
Traore ²⁶	2020	Attractive toxic sugar baits
Keita ¹⁰	2021	Indoor and outdoor malaria transmission
Diarra ³³	2021	Attractive toxic sugar baits
Traore ³⁴	2021	Antimalarial drug prescriptions
Maiga ³⁵	2021	Artemisinin-based combination therapy efficacy
Diawara ³⁶	2021	Genetic variants in <i>Plasmodium falciparum</i> malaria

junior researchers.^{37,38} Operational and implementation research training workshops are regularly organized with NMCP and partners to identify research questions of interest to control implementation improvement. The workshops organized through the WA-ICEMR research program increase awareness of malaria control program managers and district healthcare officers on the latest research findings and also generate a bank of research questions for graduate students for thesis research and career development to support local health information systems.

Leveraging WA-ICEMR research capacity to support malaria surveillance and country preparedness for elimination. Research laboratory capacity for molecular diagnostics and genomics analysis play pivotal roles in supporting the surveillance and country preparedness for malaria elimination.³⁹ For instance, molecular and genomics laboratory resources developed in the past decade have contributed to Mali's response to the COVID-19 pandemic⁴⁰ with support from the WA-ICEMR. As control efforts progress to elimination phases, strong laboratory capacity will be needed to address emerging challenges, particularly in the areas of diagnostics and drug and insecticide resistance identification. Molecular and genomic surveillance can be used to monitor trends in disease burden, detect emerging antimalarial drugs and insecticide resistance, and detect important changes in parasite/vector populations such as deletion of histidine-rich protein 2/3 genes by *P. falciparum* (hrp2/3).

Collaborations with other regional ICEMRs have enhanced the capacity for performing molecular analyses. The WA-ICEMR has leveraged next-generation sequencing platforms through other regional ICEMRs to support the NMCP with genomic surveillance of SMC and ACT drug and insecticide resistance and changes in parasite populations. ELISA techniques used in these studies are now established and fully functional in Mali, allowing for the measurement of active metabolites of amodiaquine drug levels in the blood, which will assist the NMCP in assessing compliance to SMC treatment and detecting counterfeit or substandard artemisinin drugs.^{41,42} The WA-ICEMR has built laboratory capacity to improve malaria case management, diagnostics, and other routine laboratory analyses (such as hemoglobin levels). Human resources have been expanded, including biologists, where microbiologists and laboratory technicians currently work at each WA-ICEMR study site. Additional clinicians and medical students were also provided through the WA-ICEMR

to facilitate field research activities. The presence of a highly skilled research team contributes to improving access to appropriate healthcare and malaria case management, enhancing the outcome of malaria control interventions.

Information and data sharing supporting malaria surveillance systems. The WA-ICEMR assists the NMCP's efforts to monitor and evaluate malaria control interventions, producing comprehensive, real-time research data that complement routine surveillance data of the NMCP's 15 sentinel sites established across Mali. Data routinely collected on site are shared by the Mali NMCP through the national health information system and at scientific meetings between the research team and local and national health authorities. The WA-ICEMR supported NMCP activities by routinely assisting in SMC and LLIN distribution campaigns, providing real-time data on post-distribution surveys on coverage, compliance, prevalence, and malaria incidence. The robust data management capacity established through the WA-ICEMR used electronic data capture systems, including REDCap (Vanderbilt University, Vanderbilt, TN) and REDCap mobile applications at all WA-ICEMR study sites.⁴³ These improvements provided timely and accurate surveillance data supporting Mali's health information surveillance systems. Data archived using these platforms serve as research data archives for Malian students and will ultimately be made available through the Clinical and Epidemiology Database (ClinEpiDB) resource.⁴⁴

CONCLUSIONS AND RECOMMENDATIONS

Over the past decade, the scale-up of control interventions has significantly contributed to alleviating the burden of malaria, as evidenced by notable improvements in multiple malariometric indicators with substantial reductions in malaria prevalence and incidence rates. However, the NMCP and its partners must maintain high coverage levels for preventative interventions to sustain control and prevent the resurgence of malaria. The WA-ICEMR/NMCP collaboration highlights the importance of establishing a platform for operational and implementation research, which is critically needed to determine their short- and long-term impact on malaria transmission and inform program activities. The WA-ICEMR research program is comprehensive, generating valuable data-driven evidence necessary for malaria control, and diagnosis. There is a need to expand WA-ICEMR

research on human behavioral interventions, which are instrumental in further understanding the results here and are key to achieving malaria control and, ultimately, elimination. The partnerships described here provide highly influential examples for maximizing the engagement among NMCP and its local, national, and international organizations with research communities. Thus, it is critical to empower local researchers while building the next generation of malaria researchers through partnerships to facilitate the uptake of research findings into policy and program activities. The main recommendation following these studies is to build local expertise in malaria-endemic areas such as Mali. Large-scale, multinational efforts and international partners are needed to support continued malaria laboratory and field research, especially studies focused on malaria parasites, mosquito populations, and vector biting behaviors. These approaches are likely the most plausible pathways for achieving long-term malaria elimination goals.

Received December 23, 2021. Accepted for publication July 6, 2022.

Acknowledgments: We sincerely thank the WA-ICEMR program and its scientific advisory group and study team, the communities of Dangassa, Dioro, Koulikoro, and the Mali National Malaria Control Program. We also thank Celia Jane Woodfill and the U.S. President's Malaria Initiative team for supporting the SMC implementation study. In addition, we thank our late mentor Dr. Donald J. Krogstad, whose efforts laid the groundwork for the WA-ICEMR. Finally, we thank Guilin Pharmaceutical Co., Ltd., for providing the DHA-PQ treatment for the SMC studies.

Financial support: This study was supported by the National Institutes of Health Cooperative Agreements U19AI089696 and U19AI129387 for the West African Center of Excellence for Malaria Research, U2RTW010673 for West African Center of Excellence for Global Health Bioinformatics Research Training, and D43TW008652 for the Research training program on Control of Malaria and Neglected Tropical Diseases in Mali. The study also received support from Tropical Disease Research/WHO under grant no. B20388.

Availability of data and materials: Data and materials are included as tables within this article. Data or materials not included in the manuscript are available from the corresponding author upon reasonable request, with approval from SD or MD.

Authors' addresses: Seydou Doumbia, Mahamadou Toure, Mahamadou Diakité, and Ayouba Diarra, University Clinical Research Center, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali, E-mails: sdoumbi@icermali.org, mah.toure@gmail.com, mdiakite@icermali.org, and ayouba.diarra@icermali.org. Nafomon Sogoba, Moussa Keita, Drissa Konaté, Sory Ibrahim Diawara, Sibe Thiam, Soumba Keita, Sékou F. Traoré, and Günter C. Müller, University of Sciences, Techniques and Technologies of Bamako, Mali, E-mails: nafomon@icermali.org, moussa@icermali.org, dkonate@icermali.org, sdiawara@icermali.org, sibe_t@icermali.org, soumba.keita@yahoo.fr, check@icermali.org, and guntercmuller@hotmail.com. Michael Alifrangis, Center for Medical Parasitology, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark, E-mail: mical@ sund.ku.dk. Tounkara, Department of Public Health, Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali, E-mail: moctartounkara5@gmail.com. Idrissa Cisse, Vincent Sanogo, Mahamadou H. Magassa, National Malaria Control Programme, Ministry of Health, Bamako, Mali, E-mails: idrissaciss68@yahoo.fr, sanogovincen@yahoo.fr, mahamadouhmagassa@yahoo.fr. Alyssa E. Barry, School of Medicine, Deakin University, Geelong, Australia, E-mail: a.barry@deakin.edu.au. Peter J. Winch and Hannah C. Marker, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, E-mails: pwinch@jh.u.edu and hannah.marker@jh.u.edu. Jeffrey G. Shaffer, School of Public Health and Tropical Medicine, New Orleans, LA, E-mail: jshaffer@tulane.edu. Liwang Cu, Department of Internal Medicine, University of South Florida, Tampa, FL, E-mail: liwangcui@usf.edu. John C. Beier, University of Miami, Miami, FL, E-mail: JBeier@med.miami.edu.

Jules Mihigo, U.S. President's Malaria Initiative, USAID Office, Bamako, Mali, E-mail: jmihigo@usaid.gov.

This is an open-access article distributed under the terms of the Creative Commons (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. The World Bank, 2022. *Population, Total—Mali*. Available at: <https://data.worldbank.org/indicator/SP.POP.TOTL?locations=ML>. Accessed May 23, 2022.
2. United Nations, n.d. *Africa Renewal, The Sahel: Land of Opportunities*. Available at: <https://www.un.org/africarenewal/sahel>. Accessed May 23, 2022.
3. PNLP M, 2019. *PNLP: Objectif, Zéro Paludisme au Mali à l'horizon 2030!* Available at: <https://www.jstm.org/pnlp-objectif-zero-paludisme-au-mali-a-lhorizon-2030/>. Accessed October 10, 2021.
4. INSTAT, 2018. *Mali Enquête Démographique et de Santé (DHS)*. Available at: <https://dhsprogram.com/publications/publication-fr358-dhs-final-reports.cfm>. Accessed October 15, 2021.
5. Kayentao K, Florey LS, Mihigo J, Doumbia A, Diallo A, Kone D, Doumbo O, Eckert E, 2018. Impact evaluation of malaria control interventions on morbidity and all-cause child mortality in Mali, 2000–2012. *Malar J* 17: 424.
6. Konate D et al., 2022. Effectiveness and community acceptance of extending seasonal malaria chemoprevention to children 5 to 14 years of age in Dangassa, Mali. *Am J Trop Med Hyg* 106: 648–654.
7. Coulibaly D et al., 2021. A decline and age shift in malaria incidence in rural Mali following implementation of seasonal malaria chemoprevention and indoor residual spraying. *Am J Trop Med Hyg* 104: 1342–1347.
8. Roll Back Malaria Partnership, 2008. *The Global Malaria Action Plan, for a Malaria-Free World*. Available at: <https://www.unhcr.org/4afac5629.pdf>. Accessed May 20, 2022.
9. Keita M, Baber I, Sogoba N, Maiga HM, Diallo M, Doumbia S, Traore SF, 2014. Vectorial transmission of malaria in a village along the Niger River and its fishing hamlet (Kenieroba and Fourda, Mali). *Bull Soc Pathol Exot* 107: 356–368.
10. Keita M et al., 2021. Indoor and outdoor malaria transmission in two ecological settings in rural Mali: implications for vector control. *Malar J* 20: 127.
11. Traore K et al., 2020. Ex-vivo sensitivity of *Plasmodium falciparum* to common anti-malarial drugs: the case of Kenieroba, a malaria endemic village in Mali. *Drugs R D* 20: 249–255.
12. Diakite SA et al., 2016. Stage-dependent fate of *Plasmodium falciparum*-infected red blood cells in the spleen and sickle-cell trait-related protection against malaria. *Malar J* 15: 482.
13. Rao M, 2012. Foreword. The international centers of excellence for malaria research. *Acta Trop* 121: 157.
14. Rao MR, 2015. Foreword: International Centers of Excellence for Malaria Research. *Am J Trop Med Hyg* 93: 1–4.
15. Doumbia SO et al., 2012. Improving malaria control in West Africa: interruption of transmission as a paradigm shift. *Acta Trop* 121: 175–183.
16. Shaffer JG et al., 2020. Clustering of asymptomatic *Plasmodium falciparum* infection and the effectiveness of targeted malaria control measures. *Malar J* 19: 33.
17. Kane F, Keita M, Traore B, Diawara SI, Bane S, Diarra S, Sogoba N, Doumbia S, 2020. Performance of IRS on malaria prevalence and incidence using pirimiphos-methyl in the context of pyrethroid resistance in Koulikoro region, Mali. *Malar J* 19: 286.
18. USAID, 2020. U.S. President's Malaria Initiative Mali Malaria Operational Plan FY 2020. Available at: <https://d1u4sg1s9ptc4z.cloudfront.net/uploads/2021/03/fy-2020-mali-malaria-operational-plan.pdf>. Accessed September 6, 2022.
19. Konaté D et al., 2020. Effect of routine seasonal malaria chemoprevention on malaria trends in children under 5 years in Dangassa, Mali. *Malar J* 19: 137.

20. Diawara F et al., 2017. Measuring the impact of seasonal malaria chemoprevention as part of routine malaria control in Kita, Mali. *Malar J* 16: 325.
21. Keita M, Traore S, Sogoba N, Dicko AM, Coulibaly B, Sacko A, Doumbia S, Traore SF, 2016. Susceptibility status of *Anopheles gambiae* sensu lato to insecticides commonly used for malaria control in Mali. *Bull Soc Pathol Exot* 109: 39–45.
22. Keita M, Sogoba N, Traoré B, Kané F, Coulibaly B, Traoré SF, Doumbia S, 2021. Performance of pirimiphos-methyl based Indoor Residual Spraying on entomological parameters of malaria transmission in the pyrethroid resistance region of Koulikoro, Mali. *Acta Trop* 216: 105820.
23. Sogoba N, Vounatsou P, Bagayoko MM, Doumbia S, Dolo G, Gosoniou L, Traore SF, Smith TA, Toure YT, 2008. Spatial distribution of the chromosomal forms of *Anopheles gambiae* in Mali. *Malar J* 7: 205.
24. Antonio-Nkondjio C, Ndo C, Njiokou F, Bigoga JD, Awono-Ambene P, Etang J, Ekobo AS, Wondji CS, 2019. Review of malaria situation in Cameroon: technical viewpoint on challenges and prospects for disease elimination. *Parasit Vectors* 12: 501.
25. Kariuki S, Kamau L, 2022. A new generation of long-lasting insecticidal nets. *Lancet* 399: 1202–1203.
26. Traore MM et al., 2020. Large-scale field trial of attractive toxic sugar baits (ATSB) for the control of malaria vector mosquitoes in Mali, West Africa. *Malar J* 19: 72.
27. Muller GC, Beier JC, Traore SF, Toure MB, Traore MM, Bah S, Doumbia S, Schlein Y, 2010. Successful field trial of attractive toxic sugar bait (ATSB) plant-spraying methods against malaria vectors in the *Anopheles gambiae* complex in Mali, West Africa. *Malar J* 9: 210.
28. Touré M et al., 2022. Trends in malaria epidemiological factors following the implementation of current control strategies in Dangassa, Mali. *Malar J* 21: 65.
29. Ateba FF et al., 2020. Spatio-temporal dynamic of malaria incidence: a comparison of two ecological zones in Mali. *Int J Environ Res Public Health* 17: 4698.
30. Konaté D et al., 2021. Nutritional status and asymptomatic infection in young children in two different endemic areas after seasonal malaria chemoprevention campaign in Mali. *Am J Biomed Sci Res* 12: 514–519.
31. Ateba FF et al., 2020. Predicting malaria transmission dynamics in Dangassa, Mali: a novel approach using functional generalized additive models. *Int J Environ Res Public Health* 17: 6339.
32. Keita M, Sogoba N, Kané F, Traoré B, Zeukeng F, Coulibaly B, Sodio AB, Traoré SF, Djouaka R, Doumbia S, 2021. Multiple resistance mechanisms to pyrethroids insecticides in *Anopheles gambiae* sensu lato population from Mali, West. *Afr J Infect Dis* 223: S81–S90.
33. Diarra RA et al., 2021. Testing configurations of attractive toxic sugar bait (ATSB) stations in Mali, West Africa, for improving the control of malaria parasite transmission by vector mosquitoes and minimizing their effect on non-target insects. *Malar J* 20: 184.
34. Traoré K, et al., 2021. Antimalarial drug prescription: evaluation of the healthcare professionals based on the Malian National Malaria Control Program (NMCP) Guidelines. *Int Arch Clin Pharmacol* 7. doi: 10.23937/2572-3987.1510025.
35. Maiga FO et al., 2021. Artemisinin-based combination therapy for uncomplicated *Plasmodium falciparum* malaria in Mali: a systematic review and meta-analysis. *Malar J* 20: 356.
36. Abdoulaye D, Coulibaly A, Cissé C, Wele M, Shaffer J, Doumbia S, Abbas T., Diakite M, 2021. A SNP barcode to inform genetic variation and evolution *Plasmodium falciparum* malaria in Mali. *Eur J Pharm Med Res* 8: 665–672.
37. Shaffer JG et al., 2019. Expanding research capacity in sub-Saharan Africa through informatics, bioinformatics, and data science training programs in Mali. *Front Genet* 10: 331.
38. H3Africa, 2020. *West African Center of Excellence for Global Health Bioinformatics Research Training*. Available at: <https://h3africa.org/index.php/west-african-center-of-excellence-for-global-health-bioinformatics-research-training/>. Accessed September 22, 2020.
39. WHO, 2012. *Disease Surveillance for Malaria Elimination: An Operational Manual*. Geneva, Switzerland: World Health Organization.
40. Doumbia S, Sow Y, Diakite M, Lau C-Y, 2020. Coordinating the research response to COVID-19: Mali's approach. *Health Res Policy Syst* 18: 105.
41. Ntale M, Obua C, Mukonzo J, Mahindi M, Gustafsson LL, Beck O, Ogwai-Okeng JW, 2009. Field-adapted sampling of whole blood to determine the levels of amodiaquine and its metabolite in children with uncomplicated malaria treated with amodiaquine plus artesunate combination. *Malar J* 8: 52.
42. Bacon DJ, Jambou R, Fandeur T, Le Bras J, Wongsrichanalai C, Fukuda MM, Ringwald P, Sibley CH, Kyle DE, 2007. World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. *Malar J* 6: 120.
43. Shaffer JG et al., 2019. A medical records and data capture and management system for Lassa fever in Sierra Leone: approach, implementation, and challenges. *PLoS One* 14: e0214284.
44. Ruhamyankaka E et al., 2019. ClinEpiDB: an open-access clinical epidemiology database resource encouraging online exploration of complex studies. *Gates Open Res* 3: 1661.